Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

130 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effectiveness and tolerability of olanzapine in the treatment of adolescents with schizophrenia and related psychotic disorders: results from a large, prospective, open-label study.
Dittmann RW, Meyer E, Freisleder FJ, Remschmidt H, Mehler-Wex C, Junghanss J, Hagenah U, Schulte-Markwort M, Poustka F, Schmidt MH, Schulz E, Mästele A, Wehmeier PM. Dittmann RW, et al. J Child Adolesc Psychopharmacol. 2008 Feb;18(1):54-69. doi: 10.1089/cap.2006.0137. J Child Adolesc Psychopharmacol. 2008. PMID: 18294089
Effectiveness of atomoxetine and quality of life in children with attention-deficit/hyperactivity disorder as perceived by patients, parents, and physicians in an open-label study.
Wehmeier PM, Dittmann RW, Schacht A, Minarzyk A, Lehmann M, Sevecke K, Lehmkuhl G. Wehmeier PM, et al. Among authors: dittmann rw. J Child Adolesc Psychopharmacol. 2007 Dec;17(6):813-30. doi: 10.1089/cap.2007.0025. J Child Adolesc Psychopharmacol. 2007. PMID: 18315453 Clinical Trial.
Emotional well-being in children and adolescents treated with atomoxetine for attention-deficit/hyperactivity disorder: findings from a patient, parent and physician perspective using items from the pediatric adverse event rating scale (PAERS).
Wehmeier PM, Schacht A, Lehmann M, Dittmann RW, Silva SG, March JS. Wehmeier PM, et al. Among authors: dittmann rw. Child Adolesc Psychiatry Ment Health. 2008 May 28;2(1):11. doi: 10.1186/1753-2000-2-11. Child Adolesc Psychiatry Ment Health. 2008. PMID: 18507848 Free PMC article.
Differential 3-year effects of first- versus second-generation antipsychotics on subjective well-being in schizophrenia using marginal structural models.
Lambert M, Schimmelmann BG, Schacht A, Suarez D, Haro JM, Novick D, Wagner T, Wehmeier PM, Huber CG, Hundemer HP, Dittmann RW, Naber D. Lambert M, et al. Among authors: dittmann rw. J Clin Psychopharmacol. 2011 Apr;31(2):226-30. doi: 10.1097/JCP.0b013e3182114d21. J Clin Psychopharmacol. 2011. PMID: 21346606
Sleep propensity at daytime as assessed by Multiple Sleep Latency Tests (MSLT) in patients with schizophrenia increases with clozapine and olanzapine.
Kluge M, Himmerich H, Wehmeier PM, Rummel-Kluge C, Dalal M, Hinze-Selch D, Kraus T, Dittmann RW, Pollmächer T, Schuld A. Kluge M, et al. Among authors: dittmann rw. Schizophr Res. 2012 Mar;135(1-3):123-7. doi: 10.1016/j.schres.2011.12.017. Epub 2012 Jan 16. Schizophr Res. 2012. PMID: 22257975 Clinical Trial.
Olanzapine and clozapine differently affect sleep in patients with schizophrenia: results from a double-blind, polysomnographic study and review of the literature.
Kluge M, Schacht A, Himmerich H, Rummel-Kluge C, Wehmeier PM, Dalal M, Hinze-Selch D, Kraus T, Dittmann RW, Pollmächer T, Schuld A. Kluge M, et al. Among authors: dittmann rw. Schizophr Res. 2014 Jan;152(1):255-60. doi: 10.1016/j.schres.2013.11.009. Epub 2013 Dec 5. Schizophr Res. 2014. PMID: 24315135 Clinical Trial.
130 results